A carregar...
Periodic Oxaliplatin Administration in Synergy with PER2‐Mediated PCNA Transcription Repression Promotes Chronochemotherapeutic Efficacy of OSCC
Developing chemotherapeutic resistance affects clinical outcomes of oxaliplatin treatment on various types of cancer. Thus, it is imperative to explore alternative therapeutic strategies to improve the efficacy of oxaliplatin. Here, it is shown that circadian regulator period 2 (PER2) can potentiate...
Na minha lista:
| Publicado no: | Adv Sci (Weinh) |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6839751/ https://ncbi.nlm.nih.gov/pubmed/31728273 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/advs.201900667 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|